Hong Kong has been one of the main driving markets for Critical Illness (CI) insurance in Asia. It has been the source of new product innovation over the past decades. From its initial phase of just a few conditions in the late 1980s, CI insurance grew to include more than 50 conditions by the late 1990s. By 2008, Hong Kong had already had its first multi-pay product covering the three major CI conditions with specific waiting periods between them.

The infographic below summarises the latest CI Data Insights Study (Dread Disease Survey) for the Hong Kong market. For more information about the results, please contact the CI Insights team.

A summary of the 2021 results from our CI Data Insights Study for the Hong Kong market can be accessed here.